Boehringer Ingelheim: China Approves HERNEXEOS as First Targeted Oral Treatment Option for HER2-mutant Advanced NSCLC at Initial Diagnosis
May 23, 2026
May 23, 2026
INGELHEIM AM RHEIN, Germany, May 23 -- Boehringer Ingelheim, a pharmaceutical company, issued the following news release:
* * *
China approves HERNEXEOS as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
* Therapy approved based on Phase Ib Beamion LUNG-1 trial data, demonstrating robust efficacy (75.7% objective response rate) in treatment-naive patients/1
* Expedited approval as an initial treatment in . . .
* * *
China approves HERNEXEOS as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
* Therapy approved based on Phase Ib Beamion LUNG-1 trial data, demonstrating robust efficacy (75.7% objective response rate) in treatment-naive patients/1
* Expedited approval as an initial treatment in . . .